← The Wire
PBYINasdaq
PUMA BIOTECHNOLOGY, INC.
Pharmaceutical Preparations · DE · CIK 1401667
Develops and commercializes innovative cancer treatments, currently marketing NERLYNX for HER2-positive breast cancer
$373M
Market cap
$8.19
Last close
+1.0%
1D
+6.9%
5D
345K
Volume
Price · last 39 sessions+8.8%
May 4L $6.81 · H $8.19Jun 29
328
Total filings
Jun 16, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 16, 202610-QFORM 10-QMay 7, 20268-KResults of OperationsMay 7, 2026DEFA14AFORM DEFA14AApr 28, 2026DEF 14AFORM DEF 14AApr 28, 202610-KFORM 10-KFeb 26, 20268-KResults of OperationsFeb 26, 202610-QFORM 10-QNov 6, 20258-KResults of OperationsNov 6, 202510-QFORM 10-QAug 7, 20258-KResults of OperationsAug 7, 202510-Q/AFORM 10-Q/AAug 7, 20258-KBylaw AmendmentJun 24, 20258-KShareholder VoteJun 13, 20258-KExecutive ChangeMay 9, 202510-QFORM 10-QMay 8, 20258-KResults of OperationsMay 8, 2025DEFA14AFORM DEFA14AApr 28, 2025DEF 14AFORM DEF 14AApr 28, 202510-KFORM 10-KFeb 27, 20258-KResults of OperationsFeb 27, 2025SC 13GSC 13GNov 8, 202410-QFORM 10-QNov 7, 20248-KResults of OperationsNov 7, 2024SC 13GSC 13GOct 22, 20248-KCompany UpdateSep 16, 20248-KCompany UpdateAug 15, 20248-KCompany UpdateAug 7, 202410-QFORM 10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KExecutive Change · Shareholder VoteJun 24, 20248-KCompany UpdateMay 17, 202410-QFORM 10-QMay 2, 20248-KResults of OperationsMay 2, 2024DEFA14AFORM DEFA14AApr 26, 2024DEF 14AFORM DEF 14AApr 26, 2024SC 13GSC 13GMar 29, 20248-KCompany UpdateMar 19, 202410-KFORM 10-KFeb 29, 20248-KResults of OperationsFeb 29, 20248-KReg FD DisclosureJan 18, 202410-QFORM 10-QNov 2, 20238-KResults of OperationsNov 2, 20238-KReg FD DisclosureSep 26, 2023SC 13GPUMA BIOTECHNOLOGY, INC.Sep 1, 20238-KBylaw AmendmentAug 18, 202310-QFORM 10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KShareholder VoteJun 15, 202310-QFORM 10-QMay 4, 20238-KResults of OperationsMay 4, 2023DEFA14AFORM DEFA14AApr 28, 2023DEF 14AFORM DEF 14AApr 28, 202310-KFORM 10-KMar 2, 20238-KResults of OperationsMar 2, 20238-KReg FD DisclosureJan 9, 20238-KCompany UpdateDec 16, 20228-KMaterial Agreement · Equity IssuanceDec 13, 20228-KReg FD DisclosureDec 9, 20228-KReg FD DisclosureDec 8, 20228-KCompany UpdateNov 10, 202210-QFORM 10-QNov 3, 20228-KResults of OperationsNov 3, 20228-KMaterial AgreementSep 22, 20228-KReg FD DisclosureAug 10, 202210-QFORM 10-QAug 4, 20228-KResults of OperationsAug 4, 20228-KExecutive ChangeAug 2, 2022SC 13GSC 13GJul 8, 20228-KShareholder VoteJun 17, 202210-QFORM 10-QMay 5, 20228-KResults of OperationsMay 5, 2022DEFA14AFORM DEFA14AApr 29, 2022DEF 14AFORM DEF 14AApr 29, 20228-KMaterial Agreement · Equity IssuanceMar 14, 202210-KFORM 10-KMar 3, 20228-KResults of OperationsMar 3, 2022SC 13GPUMA BIOTECHNOLOGY, INC.Feb 8, 2022SC 13GSC 13GJan 14, 20228-KReg FD DisclosureJan 10, 2022
Insider Activity
In the 90 days to Jan 7, 2026: 4 sold $419K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 7, 2026 | Auerbach Alan HPresident and CEO | Sell | 18,012 | $5.88 | $106K |
| Jan 7, 2026 | Nougues Maximo FChief Financial Officer | Sell | 6,405 | $5.88 | $38K |
| Jan 7, 2026 | Hunt Douglas MSee Remarks | Sell | 5,014 | $5.88 | $29K |
| Jan 6, 2026 | Auerbach Alan HPresident and CEO | Sell | 16,938 | $5.84 | $99K |
| Jan 6, 2026 | Nougues Maximo FChief Financial Officer | Sell | 4,540 | $5.84 | $27K |
| Jan 6, 2026 | Hunt Douglas MSee Remarks | Sell | 3,973 | $5.84 | $23K |
| Nov 11, 2025 | Miller Michael PatrickDirector | Sell | 20,000 | $4.86 | $97K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance